Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Am Vet Med Assoc ; 259(S2): 1-3, 2022 03 12.
Artigo em Inglês | MEDLINE | ID: mdl-35349468

RESUMO

In collaboration with the American College of Veterinary Pathologists.


Assuntos
Patologia Veterinária , Médicos Veterinários , Animais , Humanos , Estados Unidos
2.
Top Companion Anim Med ; 45: 100578, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34400383

RESUMO

An 11-year-old, castrated male Shetland Sheepdog presented for a 3-week history of localized nonpruritic alopecia and scaling affecting the peri-nasal region. The dog was being managed for several comorbidities, including chronic bronchitis successfully controlled with the chronic administration of inhaled fluticasone propionate. The physical examination was unremarkable aside from erythema, symmetrical alopecia, scaling and follicular casts affecting the peri-nasal region. Deep skin scrapings and histopathological examination from the lesional skin revealed several live demodex mites consistent with Demodex canis. Transcriptome analysis of lesional skin demonstrated significant downregulation of several cytokines involved in the T helper (Th) 2 and Th17 pathway with moderate upregulation of Th1 cytokine IFN-γ and T-cell recruitment chemokine CXCL10. The dog was immediately treated with oral fluralaner. Clinical signs of demodicosis resolved after 8 weeks and a trichogram was negative for live and/or dead demodex mites. The dog has remained on twice-daily administration of inhaled fluticasone and oral fluralaner every 3 months for 15 months without a demodicosis relapse, in addition to medication to manage the dog's comorbidities. To the author's knowledge, this is the first case of localized demodicosis caused by an inhaled glucocorticoid in a dog.


Assuntos
Bronquite Crônica , Doenças do Cão , Animais , Bronquite Crônica/veterinária , Doenças do Cão/induzido quimicamente , Doenças do Cão/tratamento farmacológico , Cães , Fluticasona/uso terapêutico , Masculino
3.
Can J Vet Res ; 73(2): 132-6, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19436582

RESUMO

The low molecular weight heparin (LMWH), dalteparin sodium, was administered subcutaneously (100 IU/kg) to 8 healthy cats twice daily for 13 doses. Anti-activated factor X (anti-Xa) activity was measured prior to administration (time 0), and 4, 6, 8, and 12 h after the 1st dose, 4 h after administration of the 3rd dose, and at 4, 6, 8, and 12 h after the last dose. Four cats developed measurable anti-Xa activity 4 h following a single dose, returning to baseline by 6 h. Anti-Xa activity was not detected at any time point in 4 cats. Prothrombin time (PT), activated partial thromboplastin time (APTT), and antithrombin (AT) concentrations were unaffected by LMWH administration. Dalteparin, at 100 IU/kg SC, did not achieve anti-Xa activity in 4 out of 8 cats and failed to maintain anti-Xa activity beyond 4 h in the other 4 healthy cats.


Assuntos
Anticoagulantes/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Gatos/sangue , Dalteparina/farmacologia , Fator Xa/fisiologia , Animais , Antitrombinas/metabolismo , Tempo de Tromboplastina Parcial/veterinária , Tempo de Protrombina/veterinária , Estatísticas não Paramétricas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...